Oncopeptides
1.46 SEK
+6.33 %
Less than 1K followers
ONCO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Oncopeptides
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.5 | 9.9 | 31.7 | 13.3 | 19.2 | 20.2 | 18.6 | 71.1 |
| EBITDA | -61.3 | -84.3 | -283.5 | -59.8 | -56.2 | -47.1 | ||
| EBIT | -61.3 | -84.3 | -283.5 | -59.8 | -56.2 | -47.1 | -61.5 | -224.7 |
| EBIT-% | -719.7 % | -851.1 % | -895.7 % | -450.9 % | -293.2 % | -232.8 % | -331.3 % | -315.9 % |
| Profit before taxes | -60.6 | -82.6 | -284.2 | -60.6 | -62.8 | -60.8 | -64.0 | -248.2 |
| Net income | -60.2 | -83.4 | -284.6 | -60.7 | -62.9 | -60.9 | -65.2 | -249.6 |